Myriad Genetics (MYGN) Capital Expenditures (2009 - 2026)

Myriad Genetics (MYGN) has reported Capital Expenditures for 18 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures rose 1.89% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $15.7 million (down 35.92% YoY), while the FY2025 annual figure was $15.6 million, down 17.89% from the prior year.
• Capital Expenditures rose to $5.4 million in Q1 2026 per MYGN's latest filing, from $4.7 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $23.5 million in Q1 2023 and bottomed at -$23.5 million in Q2 2023.
• Historically, Capital Expenditures has averaged $5.0 million across 5 years, with a median of $5.4 million in 2026.
• Annual changes were most pronounced in 2023 — Capital Expenditures plunged 450.75% — and 2025, when it surged 2750.0%.
• Myriad Genetics' Capital Expenditures stood at $14.6 million in 2022, then tumbled by 149.32% to -$7.2 million in 2023, then soared by 150.0% to $3.6 million in 2024, then jumped by 30.56% to $4.7 million in 2025, then rose by 14.89% to $5.4 million in 2026.
• Business Quant data shows MYGN's Capital Expenditures at $5.4 million in Q1 2026, $4.7 million in Q4 2025, and $11.6 million in Q3 2025.